The Day In Review: Curis, Inc. And Genentech, Inc. Stop Cancer Trial

July 12, 2006 -- Curis and Genentech stopped enrollment in a trial of a basal cell carcinoma drug because its biologic activity was low; ARYx Therapeutics signed a $435 million deal with Proctor and Gamble; GlaxoSmithKline said that its adjuvant increased the response for its cervical cancer vaccine; Genzyme released a stronger than expected Q2 financial report; Critical Therapeutics received a patent for using a blood-borne protein to diagnose inflammatory conditions; Xoma reminded investors it will receive a royalty from Lucentis; ZymoGenetics began a Phase I trial combining Interleukin 21 and Rituxan to treat non-Hodgkin’s lymphoma; and GPC Biotech completed submitting the non-clinical section of its FDA filing for approval of satraplatin. The Centient Biotech 200™ fell 40 points to 3616, a loss of 1.08%. More details...